Application of pea albumin in preparing composition for improving obesity and metabolic syndrome

Abstract

The present invention provides an application of pea albumin in the preparation of a composition for improving obesity and metabolic syndrome. The present invention confirms that pea albumin can effectively alleviate weight gain and excessive body fat deposition, improve glucose tolerance and reduce fat accumulation in the liver; that is, pea albumin has good effects on improving obesity, improving insulin resistance and leptin resistance, reducing fasting blood sugar and improving glucose and lipid metabolism disorders, and long-term consumption can have a beneficial effect on regulating host glucose and lipid metabolism, and has broad application prospects.

Description

Technical Field

[0001] The present application relates to the field of protein biology, and in particular to the application of pea albumin in the preparation of a composition for improving obesity and metabolic syndrome. Background Art

[0002] With the improvement of people's living standards and the acceleration of the pace of life, the incidence of obesity in the world has gradually increased, and obesity has become a serious social public health problem in the world. The "2017 Global Nutrition Report" reported that there are 1.9 billion overweight or obese people in the world, and it is expected that the global obesity rate will reach 18% and 21% in men and women in 2025. The cause of obesity is the excessive accumulation of white adipose tissue due to increased food intake or reduced energy consumption. Obesity not only affects the appearance, but also easily induces a variety of serious diseases, such as hyperlipidemia, type 2 diabetes, fatty liver, hypertension, cardiovascular disease and cancer, which seriously endangers human health and life safety.

[0003] Most of the weight loss drugs currently used in clinical practice have serious adverse reactions. Some people use traditional Chinese medicine to improve obesity and other problems, but Chinese herbal medicines still have side effects. Traditional Chinese medicines that can be used as medicines cannot be taken as food for a long time. Therefore, safety has become the biggest challenge in the development of weight loss drugs and it is also a difficulty that must be overcome.

[0004] Peas are rich in protein. Pea albumin is an important active ingredient in peas, but there is currently little research on it, especially its effects and uses, which have not yet been reported.

[0005] Currently, there is an urgent need in the art for a substitute product for existing products derived from food, which can effectively improve obesity and metabolic disorders without causing side effects. Summary of the invention

[0006] The technical problems to be solved by this application are:

[0007] Provided is an application of pea albumin in the preparation of a composition for improving obesity and metabolic syndrome, which can effectively alleviate weight gain and excessive body fat deposition, improve glucose tolerance and improve liver fatty degeneration.

[0008] The technical solution of this application is as follows:

[0009] The invention discloses an application of pea albumin in preparing a composition for improving obesity and related metabolic syndrome. The pea albumin can improve obesity caused by high fat, alleviate insulin resistance and leptin resistance caused by high fat, and improve oral glucose tolerance and insulin tolerance.

[0010] Preferably, the pea albumin is used in the preparation of a drug for improving diabetes.

[0011] Preferably, the pea albumin is used in the preparation of a drug for improving obesity.

[0012] Preferably, the pea albumin is used in the preparation of a drug for improving hyperlipidemia.

[0013] Preferably, the composition comprises one or more of food, medicine, nutritional supplement, food additive, and animal feed.

[0014] Preferably, the pea albumin is made into preparations, including tablets, capsules, granules, powders, pills, and oral liquids.

[0015] Preferably, the pea albumin can improve metabolic dysfunction caused by high fat.

[0016] The beneficial effects of the present invention are:

[0017] 1. It is the first time to confirm that the application of pea albumin in the composition for improving obesity and metabolic syndrome can improve obesity, diabetes, hyperlipidemia, effectively alleviate the subjects' weight gain and excessive body fat deposition, improve glucose tolerance and improve liver fat accumulation.

[0018] 2. The new use of pea albumin discovered by the present invention provides a new substitute for improving obesity, diabetes, hyperlipidemia, etc. It can be widely used in food, medicine, nutritional supplements, food additives, beverages, and animal feed. It can play an effective role without any side effects and has good application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 :Effects of different concentrations of pea albumin on reducing obesity caused by high fat;

[0020] Figure A: Body weight change curve; B: Total food intake; C: Representative pictures of mice; D: LEE's index; E: Serum triglyceride content; F: Serum free fatty acid content; G: Serum total cholesterol content; H: Serum high-density lipoprotein content; I: Serum low-density lipoprotein content;

[0021] Data are expressed as mean ± standard error; n = 10; * represents a significant difference compared with the control group, # represents a significant difference compared with the high-fat group, P < 0.05.

[0022] Figure 2 :Effects of different concentrations of pea albumin on adipose tissue of mice induced by high fat diet;

[0023] Figure A: Body fat percentage of mice; Figure B: Representative images of epididymal fat and inguinal fat of mice; Figure C: Epididymal fat weight; Figure D: Inguinal fat weight; Figure E: Representative images of abdominal fat of mice; Figure F: Representative images of mesenteric fat of mice; Figure G: Mesenteric fat weight; Figure H: HE staining of epididymal fat; Figure I: HE staining of inguinal fat; n = 10; Scale bar is 100 μm; * represents significant difference compared with the control group, # represents significant difference compared with the high-fat group, P < 0.05.

[0024] Figure 3 :Effects of different concentrations of pea albumin on improving high blood sugar, insulin resistance and leptin resistance caused by high fat;

[0025] Figure A: Oral glucose tolerance; B: Insulin tolerance; C: Fasting blood glucose level; D: Insulin level; E: Leptin level; Data are expressed as mean ± standard error; n = 10 independent experiments; * represents a significant difference compared with the control group, # represents a significant difference compared with the high-fat group, P < 0.05.

[0026] Figure 4 :Effects of different concentrations of pea albumin on serum biochemistry in mice;

[0027] Figure A: serum alanine aminotransferase level; Figure B: serum alanine aminotransferase level; Figure C: serum urea level; Figure D: serum total protein level; Figure E: serum albumin level; Figure F: serum globulin level; n = 10 independent experiments; * represents a significant difference compared with the control group, # represents a significant difference compared with the high-fat group, P < 0.05.

[0028] Figure 5 : Different concentrations of pea albumin alleviate high-fat-induced hepatic steatosis; HE staining of liver; n = 10 independent experiments; scale bar is 100 μm. DETAILED DESCRIPTION

[0029] The following will describe the implementation of the present invention in detail in conjunction with the drawings in this embodiment, so that the implementation process of how the present invention applies technical means to solve technical problems and achieve technical effects can be fully understood and implemented accordingly. It should be noted that as long as there is no conflict, the various features in the various embodiments of the present invention can be combined with each other, and the technical solutions formed are all within the protection scope of the present invention.

[0030] The pea albumin described in the present invention can be prepared according to Patent: 2020101549083, a method for extracting antimicrobial peptides and albumin from pea bean wastewater.

[0031] According to an embodiment of the present invention, in order to evaluate the efficacy of pea albumin in alleviating obesity and improving metabolic disorders, the experiment used a high-fat-induced mouse obesity model, and the treatment group (HFD + P) was gavaged with 0.375, 0.750 and 1.5 g / kg of pea albumin according to the weight of the mice every day, the model group (HFD) and the control group (ND) were gavaged with the same volume of normal saline, and the reagent control group (ND+P) was gavaged with 1.50 mg / kg of pea albumin. The gavage volume of all mice was 200 μL, and the experiment lasted for 8 weeks. The body weight and food intake were recorded, and oral glucose tolerance test and insulin tolerance test were performed before the end of the experiment. Blood was collected to separate serum for the detection of biochemical indicators, and organ samples were collected for subsequent analysis.

[0032] 1. Experimental animals and treatment

[0033] Four-week-old male C57BL / 6J mice (purchased from Beijing Weitonglihua Laboratory Animal Technology Co., Ltd., license number: SCXK (Beijing) 2019-0009) were housed in a mouse room at 22-25°C with a 12-h light / dark cycle per day and free access to water and food.

[0034] After 7 days of adaptation, the mice were divided into six groups according to their body weight:

[0035] (1) Control group (ND, n = 10, intragastrically administered with 200 μL of normal saline every day);

[0036] (2) control + pea albumin group (ND+P, n = 10, intragastric administration of 0.75 g / kg body weight pea albumin solution per day, with an intragastric volume of 200 μL);

[0037] (3) high-fat diet group (HFD, n = 10, intragastrically administered with 200 μL of normal saline per day);

[0038] (4) High-fat diet + pea albumin 1 (HFD+P1, n = 10, intragastric administration of 0.375 g / kg body weight pea albumin solution per day, with an intragastric volume of 200 μL);

[0039] (5) High-fat diet + pea albumin 2 (HFD+P2, n = 10, daily gavage of 0.75 g / kg body weight pea albumin solution, gavage volume of 200 μL)

[0040] (6) High-fat diet + pea albumin 3 (HFD+P3, n = 10, daily gavage of 1.50 g / kg body weight pea albumin solution, gavage volume of 200 μL), the experimental period was 8 weeks, body weight and feed intake were measured once a week.

[0041] 2. Determination of fasting glucose concentration

[0042] Blood was collected from the tail vein of mice and immediately measured and recorded using a Roche blood glucose meter.

[0043] 3. Determination of body fat in mice

[0044] One week before the end of the experiment, the body fat rate of mice was measured using a live mouse body fat analyzer (small nuclear magnetic resonance); after the end of the experiment, the mice were fasted for 6 hours, blood was collected by eyeball method, and then the mice were killed by cervical dislocation. Subcutaneous inguinal fat, abdominal epididymal fat and mesenteric fat were separated and collected, weighed, recorded and photographed. The isolated mouse liver tissue was fixed in 4% paraformaldehyde for 24 hours, washed 3 times with saline, and stored in 70% ethanol for subsequent tissue sectioning.

[0045] 4. Serum biochemical analysis

[0046] Serum triglycerides (TG), total cholesterol (TC), free fatty acids (NEFA), high-density lipoprotein (HDL-C), low-density lipoprotein (LDL-C), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total protein (TP) and albumin (ALB) were determined according to the kit instructions provided by Nanjing Jiancheng Biotechnology Co., Ltd.

[0047] The levels of insulin and leptin in serum were determined according to the kit instructions provided by Shanghai Bio-Tech Biotechnology Co., Ltd.

[0048] 5. Oral Glucose Tolerance Test (OGTT)

[0049] One week before the end of the experiment, an oral glucose tolerance test was performed on mice that had been fasted overnight. A 50% glucose solution was gavaged into the mice at a dose of 2 g / kg body weight. Blood was collected from the tail vein, and blood glucose concentration was measured using a glucometer at 0, 30, 60, 90, and 120 minutes after glucose administration.

[0050] 6. Insulin tolerance test (ITT)

[0051] Before the end of the experiment, mice were starved for 4 h, and each mouse was intraperitoneally injected with insulin at 0.75 U / kg body weight. Blood was collected from the tail vein, and blood glucose concentration was measured using a glucometer at 0, 30, 60, 90, and 120 minutes after insulin administration.

[0052] 7. Liver lipid analysis

[0053] Mouse liver samples were fixed with 4% paraformaldehyde and embedded in paraffin. 5 μm sections were stained with hematoxylin to examine their cellular structure and lipid accumulation. The quantification of hepatic triglycerides and free fatty acids was performed in the same manner as the serum analysis.

[0054] 8. Statistical analysis

[0055] Data are presented as mean ± SEMs and analyzed by one-way ANOVA. Differences were determined by Duncan's multiple comparisons using GraphPadPrism version 7.0 (GraphPad Software, San Diego, CA, USA). P A value < 0.05 was considered significant.

[0056] 9. Results

[0057] like Figure 1 As shown, compared with the HFD group, daily oral administration of pea albumin 0.75 g / kg and 1.5 g / kg significantly reduced ( P < 0.05) High-fat diet-induced obesity in mice ( Figure 1 A), while the daily gavage of 0.375 g / kg pea albumin significantly reduced the obesity of mice induced by high-fat diet only at the seventh and eighth weeks; compared with the HFD group, daily administration of different concentrations of pea albumin did not affect the total food intake of mice ( P > 0.05); compared with the HFD group, oral administration of pea albumin was significantly ( P < 0.05) improved the LEE's index of mice ( Figure 1 C and D). Compared with the HFD group, pea albumin significantly ( P < 0.05) to reduce serum triglycerides ( Figure 1 E), free fatty acids ( Figure 1 F), total cholesterol ( Figure 1 G) content, but not serum high-density lipoprotein cholesterol (Figure IH) and low-density lipoprotein cholesterol ( Figure 1 There was no significant effect on the level of I P > 0.05). Therefore, pea albumin can effectively alleviate obesity and abnormal blood lipid metabolism in mice induced by high-fat diet.

[0058] Depend on Figure 2 It can be seen that compared with the HFD group, the results of nuclear magnetic resonance imaging of the body composition of mice showed that pea albumin treatment significantly reduced ( P < 0.05) mice had a reduced body fat percentage ( Figure 2 A and B); Representative images and statistical results of epididymal fat and inguinal fat in mice showed that oral administration of pea albumin significantly reduced ( P < 0.05) high-fat diet-induced epididymal fat ( Figure 2 C) and inguinal fat ( Figure 2 D) increase; the separation and weighing of mesenteric fat showed that pea albumin significantly reduced (P < 0.05) mesenteric fat content ( Figure 2 F and G); In addition, HE staining of epididymal fat and inguinal fat obtained by dissection revealed that pea albumin could significantly ( P < 0.05) to prevent adipocyte hypertrophy induced by high-fat diet ( Figure 2 H and I). Therefore, pea albumin can significantly reduce obesity and adipocyte hypertrophy induced by high-fat diet.

[0059] Depend on Figure 3 It can be seen that compared with the HFD group, daily administration of pea albumin significantly reduced ( P < 0.05) fasting blood glucose values ​​of mice at eight weeks of age ( Figure 3 C) Insulin levels ( Figure 3 D) and leptin levels ( Figure 3 E); In addition, oral administration of pea albumin 0.75 g / kg and 1.5 g / kg significantly reduced ( P < 0.05) improved oral glucose tolerance in mice ( Figure 3 A), while gavage of 375 mg / kg pea albumin did not significantly improve oral glucose tolerance ( P > 0.05); insulin tolerance test showed that oral administration of 1.5 g / kg pea albumin significantly improved ( P < 0.05) Insulin sensitivity in high-fat mice ( Figure 3 B), while low and medium concentrations of pea albumin had no significant effect on improving the insulin sensitivity of mice ( P > 0.05). Therefore, pea albumin can significantly alleviate the glucose metabolism disorder induced by high-fat diet in mice.

[0060] Depend on Figure 4 It can be seen that compared with the HFD group, pea albumin significantly ( P < 0.05) alleviated liver damage caused by feeding a high-fat diet (ALT, Figure 4 A); In addition, compared with the HFD group, oral administration of 1.5 g / kg pea albumin significantly reduced ( P < 0.05) AST activity, but low and medium concentrations of pea albumin did not effectively reduce ( P > 0.05) High-fat diet induced an increase in AST activity ( Figure 4 B); Detection of serum protein method, intragastric administration of pea albumin to total serum protein ( Figure 4 D) albumin ( Figure 4 E) and globulin ( Figure 4 There was no significant difference in the content of F P< 0.05). Therefore, pea albumin can alleviate liver damage induced by high-fat diet, but has no effect on serum protein levels.

[0061] Depend on Figure 5 It can be seen that compared with the HFD group, the results of HE staining of the liver showed that oral administration of 1.5 g / kg pea albumin can reduce the accumulation of fat in the liver caused by a high-fat diet (the white hollow part in the section staining), and medium concentrations can also partially reduce the accumulation of fat in the liver. The effect of low-concentration pea albumin on reducing fat accumulation in the liver is not obvious. Therefore, pea albumin can significantly reduce the accumulation of fat in the liver.

[0062] In summary, pea albumin can significantly improve obesity, insulin resistance, lipid metabolism disorders, etc. in high-fat diet-induced obese mice. It has a certain effect in improving obesity and its related metabolic diseases, improving leptin resistance, lowering fasting blood sugar, and improving metabolic disorders.

[0063] Therefore, pea albumin can be used in the preparation of a composition for improving obesity and related metabolic syndromes, such as in the preparation of a drug for improving diabetes, in the preparation of a drug for improving diabetes, and in the preparation of a drug for improving hyperlipidemia. The composition includes one or more of food, medicine, nutritional supplement, food additive, beverage, and animal feed. The pea albumin can be made into a preparation, and the preparation includes tablets, capsules, granules, powders, pills, and oral liquids.

[0064] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, without contradiction.

[0065] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.

Claims

1. Use of pea albumin as the sole active ingredient in preparing a composition for improving obesity and related metabolic syndrome, characterized in that: The improvement of obesity and related metabolic syndrome is to improve obesity caused by high fat, alleviate sugar metabolism disorder caused by high fat, and alleviate abnormal blood lipid metabolism caused by high fat.

2. The use according to claim 1, characterized in that: The relief of sugar metabolism disorder caused by high fat includes alleviating insulin resistance caused by high fat and improving oral glucose tolerance.

3. The use according to claim 1, characterized in that: The composition is selected from the group consisting of food, medicine, nutritional supplement, food additive, and animal feed.

4. The use according to claim 1, characterized in that: The pea albumin is made into a preparation, and the preparation is selected from tablets, capsules, granules, powders, pills, and oral liquids.

Images